Bleeding secondary to the use of thrombolytic agent in a patient with recent renal lithotripsy.
We feel that while our patient succumbed to complications of his extensive anterior myocardial infarction, the devastating renal, subcapsular, and retroperitoneal hemorrhage as well as the cerebral hemorrhage certainly appeared to hasten his demise. From this experience, we now consider recent renal lithotripsy to be a major contraindication to the use of thrombolytic agents. Logically, the time frame for omitting thrombolytic therapy following renal lithotripsy should be similar to that of other major surgical procedures, approximately four to six weeks.
Bleckley
J E
JE
Morse
H G
HG
D006470:Hemorrhage / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D007669:Kidney Calculi / Q000628:therapy; D007674:Kidney Diseases / Q000175:diagnosis / Q000209:etiology*; D008096:Lithotripsy / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D010959:Tissue Plasminogen Activator